TSX runs higher on rate cut expectations
LONDON - Morphic Medical (TASE:BLWV) Inc. (MMI), a medical device company focused on minimally invasive treatments for obesity and cardiometabolic disorders, has appointed Mike Gutteridge as its new Chief Executive Officer, according to a Tuesday statement from Crystal Amber Fund Limited, which owns 96.7% of MMI.
Gutteridge, who previously served as MMI’s Commercial Director, succeeds Joe Virgilio, who stepped down after five years with the company. The leadership change comes shortly after MMI received CE Mark certification for its RESET® therapy last month.
The CE Mark designation certifies that the RESET® therapy has met European Commission requirements for safety, health, and environmental protection. According to the company statement, this makes it the first endoscopic, non-surgical treatment approved for both obesity and Type 2 diabetes in Europe, potentially providing access to treatment for an estimated 93 million European patients living with these conditions.
"I am honoured to become Chief Executive," Gutteridge said in the statement. "With over thirty years in the MedTech sector spanning clinical innovation, commercial strategy, market development and reimbursement, I am energised by the opportunity to lead Morphic into its next phase."
Christopher Waldron, Chairman of Crystal Amber Fund, thanked the outgoing CEO for "delivering CE Mark and for all his efforts and commitment to innovation and patient care," adding that the board is "excited that Mike, who brings a successful track record of international commercialisation, will be leading MMI as it enters a new and exciting stage of growth."
The announcement was made in a press release from Crystal Amber Fund Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.